Instil Company Overview, Contact Details & Competitors

Q: What is Instil's official website and social media links?

Instil's official website is instil.io. Instil has social profiles on LinkedIn.

Q: How many employees does Instil have currently?

Instil has approximately 13 employees.

Q: What technology does Instil use?

Instil's tech stack includes YouTube, Twitter, GitHub, JSON-LD, Lodash.

Q: What is Instil's NAICS code?

Instil's NAICS code is 5112 (Software Publishers).

Insights

Gathering insights about Instil…

Similar companies to Instil

Instil Tech Stack

Instil uses 8 technology products and services including OpenX, Amazon Web Services, HubSpot Content Hub, and more. Explore Instil's tech stack below.

OpenX
Advertising
Amazon Web Services
Cloud Hosting
HubSpot Content Hub
Content Management System
HubSpot Cookie Policy Banner
Cookie Compliance
jQuery
Javascript Libraries
Auxilia
Payment Processing
OpenResty
Web Servers
Twitter
Widgets

Media & News

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent Highlights Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027 “We continue to make progress refining Instil's strategy and positioning the company for its next phase of growth,” said Bronson Crouch, Chief Executive Officer, Instil Bio.
May 15, 2026 | www.globenewswire.com
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth quarter and full year 2025 financial results and provided a corporate update. Recent Highlights: In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. to terminate the license and collaboration agreement for AXN-2510 and AXN-27M.
Mar 27, 2026 | www.globenewswire.com
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy.
Feb 24, 2026 | www.globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Feb 12, 2026 | www.prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Feb 03, 2026 | www.globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Jan 29, 2026 | www.prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Jan 27, 2026 | www.globenewswire.com

Instil's Email Address Formats

Instil uses at least 1 format(s):

Instil Email Formats	Example	Percentage
First@instil.io	John@instil.io	75%
FirstL@instil.io	JohnD@instil.io	18%
Last@instil.io	Doe@instil.io	5%
FLast@instil.io	JDoe@instil.io	2%

Frequently Asked Questions

Where is Instil's headquarters located?

Instil's main headquarters is located at Los Angeles, California United States. The company has employees across 2 continents, including North AmericaAsia.

What is Instil's stock symbol?

Instil is a publicly traded company; the company's stock symbol is TIL.

What is Instil's official website and social media links?

Instil's official website is instil.io and has social profiles on LinkedIn Crunchbase.

What is Instil's NAICS code?

Instil's NAICS code is 5112 - Software Publishers.

How many employees does Instil have currently?

As of May 2026, Instil has approximately 13 employees across 2 continents, including North AmericaAsia. Key team members include Ceo: S. R. D.Director Of Engineering: C. R.Senior Software Engineer: Y. F.. Explore Instil's employee directory with LeadIQ.

What industry does Instil belong to?

Instil operates in the Software Development industry.

What technology does Instil use?

Instil's tech stack includes OpenXAmazon Web ServicesHubSpot Content HubHubSpot Cookie Policy BannerjQueryAuxiliaOpenRestyTwitter.

What is Instil's email format?

Instil's email format typically follows the pattern of First@instil.io. Find more Instil email formats with LeadIQ.

When was Instil founded?

Instil was founded in 2020.

Insights

Similar companies to Instil

DTS

Audionamix

LANDR Audio Inc.

Sonix

Accusonus

Instil Tech Stack

Media & News

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

Instil's Email Address Formats

Frequently Asked Questions

Where is Instil's headquarters located?

What is Instil's stock symbol?

What is Instil's official website and social media links?

What is Instil's NAICS code?

How many employees does Instil have currently?

What industry does Instil belong to?

What technology does Instil use?

What is Instil's email format?

When was Instil founded?

Instil

Company Overview

Media & News

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?